Immunome Inc.(IMNM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMNM Immunome Inc.

Market Closed 01-23 16:00:00 EST

25.87

+0.05

+0.19%

盘后25.79

-0.08-0.31%

18:53 EST

High26.36	Low24.85	Vol2.08M
Open25.63	D1 Closing25.82	Amplitude5.85%
Mkt Cap2.85B	Tradable Cap2.43B	Total Shares110.34M
T/O53.45M	T/O Rate2.22%	Tradable Shares93.80M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"IMNM","market":"US","secType":"STK","nameCN":"Immunome Inc.","latestPrice":25.87,"timestamp":1769202000000,"preClose":25.82,"halted":0,"volume":2080075,"hourTrading":{"tag":"盘后","latestPrice":25.79,"preClose":25.87,"latestTime":"18:53 EST","volume":22975,"amount":593572.0133,"timestamp":1769212420580,"change":-0.08,"changeRate":-0.003092,"amplitude":0.037882},"delay":0,"changeRate":0.00193648334624325,"floatShares":93799100,"shares":110335277,"eps":-2.96,"marketStatus":"Market Closed","change":0.05,"latestTime":"01-23 16:00:00 EST","open":25.63,"high":26.36,"low":24.85,"amount":53447348.23855,"amplitude":0.058482,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.96,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1769418000000},"marketStatusCode":7,"adr":0,"listingDate":1601611200000,"exchange":"NASDAQ","adjPreClose":25.82,"preHourTrading":{"tag":"盘前","latestPrice":25.6294,"preClose":25.82,"latestTime":"09:19 EST","volume":178,"amount":4567.089112,"timestamp":1769177953870,"change":-0.1906,"changeRate":-0.007382,"amplitude":0.006971},"postHourTrading":{"tag":"盘后","latestPrice":25.79,"preClose":25.87,"latestTime":"18:53 EST","volume":22975,"amount":593572.0133,"timestamp":1769212420580,"change":-0.08,"changeRate":-0.003092,"amplitude":0.037882},"volumeRatio":0.8469358679986164,"impliedVol":0.9388,"impliedVolPercentile":0.51},"requestUrl":"/m/hq/s/IMNM","defaultTab":"news","newsList":[{"id":"2603986858","title":"Immunome Price Target Maintained With a $31.00/Share by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2603986858","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603986858?lang=en_us&edition=fundamental","pubTime":"2026-01-15 22:28","pubTimestamp":1768487280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMNM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 15, 2026 09:28 ET (14:28 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","IMNM","BK4139"],"gpt_icon":0},{"id":"2603988007","title":"Wedbush Reaffirms Their Buy Rating on Immunome (IMNM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603988007","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603988007?lang=en_us&edition=fundamental","pubTime":"2026-01-15 21:36","pubTimestamp":1768484171,"startTime":"0","endTime":"0","summary":"Wedbush analyst maintained a Buy rating on Immunome today and set a price target of $31.00. The word on The Street in general, suggests a Strong Bu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wedbush-reaffirms-their-buy-rating-on-immunome-imnm-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wedbush-reaffirms-their-buy-rating-on-immunome-imnm-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMNM"],"gpt_icon":0},{"id":"2602186453","title":"Immunome Grants Stock Options to New Employees Under 2024 Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2602186453","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602186453?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:05","pubTimestamp":1767906324,"startTime":"0","endTime":"0","summary":"Immunome Inc. has granted non-statutory stock options to three new employees under its 2024 Inducement Plan. The awards cover a total of 93,000 shares of common stock, with an exercise price of $20.82 per share, which was the company’s closing price on January 2, 2026. The options will vest over four years: 25% on the one-year anniversary of the vesting commencement date, and the remaining shares vesting monthly over the following 36 months, contingent on continued employment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunome Inc. published the original content used to generate this news brief via Business Wire  on January 08, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL3FD3Fr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMNM","BK4563"],"gpt_icon":0},{"id":"2595745844","title":"Immunome Inc. CEO Clay B. Siegall Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2595745844","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595745844?lang=en_us&edition=fundamental","pubTime":"2025-12-31 07:48","pubTimestamp":1767138501,"startTime":"0","endTime":"0","summary":"Clay B. Siegall, President and CEO of Immunome Inc., reported the acquisition of common shares of Immunome Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunome Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 30, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251230:nNDL3bxtS5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Immunome Inc. CEO Clay B. Siegall Acquires Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMNM","BK4563"],"gpt_icon":0},{"id":"2594425033","title":"Immunome (IMNM): Assessing Valuation After Strong Phase 3 Varegacestat Data and $400 Million Equity Raise","url":"https://stock-news.laohu8.com/highlight/detail?id=2594425033","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594425033?lang=en_us&edition=fundamental","pubTime":"2025-12-26 07:20","pubTimestamp":1766704858,"startTime":"0","endTime":"0","summary":"Immunome (IMNM) just delivered a big one two for investors, first unveiling strong Phase 3 RINGSIDE data for varegacestat in desmoid tumors, then swiftly raising about $400 million through a follow on stock offering.\nSee our latest analysis for Immunome.\nThose blockbuster Phase 3 results and the follow on raise have not gone unnoticed, with the share price climbing to $22.33 and delivering a 90 day share price return of about 120 percent, while the three year total shareholder return is...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imnm/immunome/news/immunome-imnm-assessing-valuation-after-strong-phase-3-vareg","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imnm/immunome/news/immunome-imnm-assessing-valuation-after-strong-phase-3-vareg","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4563","EQR","BK4139","IMNM","BK4585","BK4215","BK4588"],"gpt_icon":0},{"id":"2593458914","title":"Immunome Inc. Director Isaac Barchas Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2593458914","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593458914?lang=en_us&edition=fundamental","pubTime":"2025-12-24 05:42","pubTimestamp":1766526123,"startTime":"0","endTime":"0","summary":"Isaac Barchas, Director of Immunome Inc., reported a disposal of common shares of Immunome Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunome Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 23, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDL945GDV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Immunome Inc. Director Isaac Barchas Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMNM","BK4563"],"gpt_icon":0},{"id":"2593248200","title":"Immunome CTO Philip Tsai Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2593248200","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593248200?lang=en_us&edition=fundamental","pubTime":"2025-12-22 20:33","pubTimestamp":1766406812,"startTime":"0","endTime":"0","summary":"Philip Tsai, Chief Technical Officer of Immunome Inc., reported the acquisition of common shares of Immunome Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunome Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 22, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDL37L5X6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Immunome CTO Philip Tsai Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMNM","BK4139","BK4563"],"gpt_icon":0},{"id":"2592146253","title":"Clay Siegall Bought 5.8% More Shares In Immunome","url":"https://stock-news.laohu8.com/highlight/detail?id=2592146253","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592146253?lang=en_us&edition=fundamental","pubTime":"2025-12-20 21:17","pubTimestamp":1766236675,"startTime":"0","endTime":"0","summary":"Those following along with Immunome, Inc. ( NASDAQ:IMNM ) will no doubt be intrigued by the recent purchase of shares...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imnm/immunome/news/clay-siegall-bought-58-more-shares-in-immunome","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imnm/immunome/news/clay-siegall-bought-58-more-shares-in-immunome","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BK4563","IMNM"],"gpt_icon":0},{"id":"2592505182","title":"Immunome CEO Clay B. Siegall Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592505182","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592505182?lang=en_us&edition=fundamental","pubTime":"2025-12-19 06:04","pubTimestamp":1766095471,"startTime":"0","endTime":"0","summary":"Clay B. Siegall, President and CEO of Immunome Inc., reported the acquisition of common shares of Immunome Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunome Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 18, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL9qSGz5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Immunome CEO Clay B. Siegall Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","BK4139","IMNM"],"gpt_icon":0},{"id":"2592091186","title":"BUZZ-U.S. STOCKS ON THE MOVE-Spotify, Robinhood Markets, Cannabis stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2592091186","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592091186?lang=en_us&edition=fundamental","pubTime":"2025-12-17 23:40","pubTimestamp":1765986030,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Spotify, Robinhood Markets, Cannabis stocksEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call ne","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nL6N3XN14O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MCK","CVX","HL","GIS","FCF","FDX","VERU","ABM","COP","COR","FCX","IMNM","CVS","XOM","KYMR","TXRH","CYTK","ALB","AVTR","PANW","VSCO","FISI","LNG","VOR","NFE","HUT","NWBI","WSBC","CNX","KYTX","SPOT","TPL","WMB","XENE","NUE","NEO","APOG","COUR","FTNT","PSKY","NEM","SCCO","WAT","DHR","JBL","HOOD"],"gpt_icon":1},{"id":"2592913067","title":"BUZZ-U.S. STOCKS ON THE MOVE-Jabil, Texas Pacific Land, Texas Roadhouse","url":"https://stock-news.laohu8.com/highlight/detail?id=2592913067","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592913067?lang=en_us&edition=fundamental","pubTime":"2025-12-17 22:14","pubTimestamp":1765980847,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Jabil, Texas Pacific Land, Texas RoadhouseEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call new","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nL6N3XN0N8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVTR","HUT","HL","UDMY","CYTK","DHR","AIR","IMNM","XENE","FISI","VSCO","FTNT","USAW.SI","KOD","CDE","NEO","NWBI","PSKY","LU2063271972.USD","WAT","TXRH","VERU","SCCO","GIS","FDX","JBL","COR","CVS","NEM","APOG","NUE","TPL","PANW","ABM","FCX","TE","WSBC","MCK","COUR","KYMR","FCF","LU2750360641.GBP","VOR","ALB","STLD"],"gpt_icon":1},{"id":"2592699095","title":"BUZZ-Immunome slips after $400 mln stock sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2592699095","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592699095?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:00","pubTimestamp":1765976414,"startTime":"0","endTime":"0","summary":"** Shares of biotech co Immunome IMNM.O down 3.5% premarket at $22.65 after $400 mln follow-on priced. ** Bothell, Washington-based IMNM late Tues announced selling ~18.6 mln shares at $21.50, an 8.4% discount to last sale. IMNM shares jumped nearly 16% on Mon after co said its experimental drug, varegacestat, met main goal in late-stage study for patients with desmoid tumors. ** After the bell Mon, co launched $400 mln offering. IMNM shares added another 3.7% on Tues. ** Co plans to use net offering proceeds to fund potential commercial launch of varegacestat, continued commercial development and manufacturing scale-up for varegacestat, continued clinical and preclinical development of other pipeline assets, among other uses, per the offering prospectus. ** Leerink, JP Morgan, TD Cowen, Goldman and Guggenheim are joint bookrunners. ** Stephens analyst Melissa Roberts says in note that IMNM's capital raise qualifies for \"immediate adjustment in market indexes\", and estimates passive de","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nL6N3XN0XK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0070302665.USD","LU1914381329.SGD","LU1670628061.USD","LU2756315318.SGD","IE00B775SV38.USD","IE00BDRTCR15.USD","LU0787776722.HKD","LU1720051017.SGD","LU1720051108.HKD","LU1988902786.USD","LU0964807845.USD","LU2213496289.HKD","IE0034235295.USD","LU0496365809.HKD","LU1894683348.USD","LU0971096721.USD","LU0942090050.USD","BK4585","BK4139","LU2552382058.USD","LU1496350171.SGD","LU2237443978.SGD","IE00BFXG1179.USD","LU0208291251.USD","LU2381873111.SGD","IE0034235303.USD","LU0048584097.USD","LU0943347566.SGD","IMNM","BK4207","LU2357305700.SGD","IE00BZ1G4Q59.USD","LU0320765489.SGD","LU0640476718.USD","LU0234572021.USD","LU1548497426.USD","LU2242649171.HKD","IE00BKDWB100.SGD","LU1668664300.SGD","LU0211331839.USD","LU1366192091.USD","LU1162221912.USD","LU0006306889.USD","IE00BBT3K403.USD","LU2505996681.GBP","IE00BHPRN162.USD","LU0106831901.USD","LU2430703095.HKD","LU0203347892.USD","LU1084165304.USD"],"gpt_icon":0},{"id":"2592497952","title":"Immunome Announces Pricing Of Public Offering Of 18,625,000 Shares At $21.50 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2592497952","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592497952?lang=en_us&edition=fundamental","pubTime":"2025-12-17 10:15","pubTimestamp":1765937706,"startTime":"0","endTime":"0","summary":"Dec 16 (Reuters) - Immunome Inc ::*IMMUNOME ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK*IMMUNOME INC - PRICES PUBLIC OFFERING OF 18,625,000 SHARES AT $21.50 EACH  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 17-DEC-202501:16:00.07 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nRSD7hpQvs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMNM","BK4139","BK4563"],"gpt_icon":0},{"id":"2592173951","title":"Immunome Inc - Prices Public Offering of 18,625,000 Shares at $21.50 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2592173951","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592173951?lang=en_us&edition=fundamental","pubTime":"2025-12-17 09:16","pubTimestamp":1765934160,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA6NBPV3:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4563","BK4139","IMNM"],"gpt_icon":0},{"id":"2592939749","title":"ADVISORY-Alert from Equity-Insider.com was published in error and has been withdrawn","url":"https://stock-news.laohu8.com/highlight/detail?id=2592939749","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592939749?lang=en_us&edition=fundamental","pubTime":"2025-12-17 01:43","pubTimestamp":1765907029,"startTime":"0","endTime":"0","summary":"ADVISORY-Alert from Equity-Insider.com was published in error and has been withdrawnAn alert on cancer drug developers was inadvertently filed off a commentary by Equity-Insider.com and tagged to Immu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nTUA1LWBBS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","PRLD","RLAY","ONCY","BK4139","CNTX","IMNM","BK4505","BK4007"],"gpt_icon":0},{"id":"2592939613","title":"Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards","url":"https://stock-news.laohu8.com/highlight/detail?id=2592939613","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592939613?lang=en_us&edition=fundamental","pubTime":"2025-12-17 01:18","pubTimestamp":1765905480,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nTUA1LWBBS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PRLD","BK4563","ONCY","BK4505","BK4139","IMNM","RLAY","CNTX","BK4007"],"gpt_icon":0},{"id":"2591987004","title":"Immunome Is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2591987004","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591987004?lang=en_us&edition=fundamental","pubTime":"2025-12-16 21:58","pubTimestamp":1765893480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMNM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 16, 2025 08:58 ET (13:58 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","IMNM","BK4139"],"gpt_icon":0},{"id":"2591622377","title":"Immunome Inc - Offering $400 Mln of Common Stock - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2591622377","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591622377?lang=en_us&edition=fundamental","pubTime":"2025-12-16 05:46","pubTimestamp":1765835187,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nFWN3XL0NK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4563","IMNM","BK4139"],"gpt_icon":0},{"id":"2591624985","title":"BUZZ-Immunome dips after launching $400 mln stock offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2591624985","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591624985?lang=en_us&edition=fundamental","pubTime":"2025-12-16 05:21","pubTimestamp":1765833665,"startTime":"0","endTime":"0","summary":"** Shares of biotech co Immunome IMNM.O fall 2% post-market to $22.19 as it seeks equity. ** Bothell, Washington-based IMNM commences $400 mln stock offering. ** IMNM shares closed up 15.7% at $22.64 on Mon after co said its experimental drug, varegacestat, met main goal in late-stage study for patients with a rare type of tumor. ** Leerink, J.P. Morgan, TD Cowen, Goldman and Guggenheim are joint bookrunners for the offering. ** With ~91.7 mln shares outstanding, co has ~$2.1 bln market cap** Through Mon, shares up 113% YTD. ** All 13 analysts rate shares \"strong buy\" or \"buy\"; median PT of $32 up from $22 a month ago, per LSEG data","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nL6N3XL14K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4563","IMNM"],"gpt_icon":0},{"id":"2591624674","title":"Immunome Plans $400 Million Public Stock Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2591624674","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591624674?lang=en_us&edition=fundamental","pubTime":"2025-12-16 05:20","pubTimestamp":1765833635,"startTime":"0","endTime":"0","summary":"Immunome  said late Monday it intends to launch an underwritten public offering of $400 million of common stock.The underwriters will have a 30-day option to purchase up to $60 million in additional shares.The company said there is no guarantee the offering will be completed or what its final size or terms may be.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4563","IMNM"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immunome.com","stockEarnings":[{"period":"1week","weight":0.1544},{"period":"1month","weight":0.1585},{"period":"3month","weight":0.6488},{"period":"6month","weight":1.3799},{"period":"1year","weight":1.5313},{"period":"ytd","weight":0.2044}],"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":-0.0017},{"period":"3month","weight":0.0177},{"period":"6month","weight":0.0818},{"period":"1year","weight":0.1303},{"period":"ytd","weight":0.0107}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01 that targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.833333,"avgChangeRate":0.396273},{"month":2,"riseRate":0.4,"avgChangeRate":0.326996},{"month":3,"riseRate":0.4,"avgChangeRate":-0.090619},{"month":4,"riseRate":0.2,"avgChangeRate":-0.143676},{"month":5,"riseRate":0.6,"avgChangeRate":-0.004931},{"month":6,"riseRate":0.4,"avgChangeRate":0.006649},{"month":7,"riseRate":0.6,"avgChangeRate":0.091554},{"month":8,"riseRate":0.2,"avgChangeRate":0.026473},{"month":9,"riseRate":0.6,"avgChangeRate":0.199621},{"month":10,"riseRate":0.4,"avgChangeRate":0.031075},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.006249},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.09277}],"exchange":"NASDAQ","name":"Immunome Inc.","nameEN":"Immunome Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immunome Inc.(IMNM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Immunome Inc.(IMNM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Immunome Inc.,IMNM,Immunome Inc.股票,Immunome Inc.股票老虎,Immunome Inc.股票老虎国际,Immunome Inc.行情,Immunome Inc.股票行情,Immunome Inc.股价,Immunome Inc.股市,Immunome Inc.股票价格,Immunome Inc.股票交易,Immunome Inc.股票购买,Immunome Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immunome Inc.(IMNM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Immunome Inc.(IMNM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}